Biofilm compared to conventional antimicrobial susceptibility of Stenotrophomonas maltophilia Isolates from cystic fibrosis patients.
about
Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic optionsColistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapyAntibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infectionsInfection and colonization by Stenotrophomonas maltophilia: antimicrobial susceptibility and clinical background of strains isolated at a tertiary care centre in Hungary.Stenotrophomonas maltophilia bloodstream infection in patients with hematologic malignancies: a retrospective study and in vitro activities of antimicrobial combinations.Quantification of Pseudomonas aeruginosa in multispecies biofilms using PMA-qPCR.Effects of Fluoroquinolones and Azithromycin on Biofilm Formation of Stenotrophomonas maltophilia.In vitro activity of levofloxacin against planktonic and biofilm Stenotrophomonas maltophilia lifestyles under conditions relevant to pulmonary infection in cystic fibrosis, and relationship with SmeDEF multidrug efflux pump expression.Effect of High-Dose Antimicrobials on Biofilm Growth of Achromobacter Species Isolated from Cystic Fibrosis Patients.Activity of Tobramycin against Cystic Fibrosis Isolates of Burkholderia cepacia Complex Grown as Biofilms.In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients.New strategies against Stenotrophomonas maltophilia: a serious worldwide intrinsically drug-resistant opportunistic pathogen.Anti-biofilm and Anti-Virulence Efficacy of Celastrol Against Stenotrophomonas maltophilia.
P2860
Q26782924-74CA899B-FCF2-4155-BC85-5DE9C96A3C1AQ27014993-CDC1326E-5717-4E73-A93F-F430DA8287E3Q33786154-7D6B439D-8157-4CDA-9C14-F9B3E64C4495Q35018533-CF9BB32D-8194-4A8B-9D51-745F8E4066BAQ35108518-19594F88-78AF-47C8-8D2F-ADA2976ED16BQ35145697-520F7A5B-3EDD-42DC-B501-0845DF249063Q37089532-19CE5A02-F1FB-4B75-82D2-7C7E2FF367D3Q40652733-6FA5C0F5-30FF-4E05-BB93-5FCAFFC8556DQ40926645-F95188E6-A4B5-466B-9BC2-E89BF74A5845Q40936412-E02F7703-8C69-494B-8659-A1B594CE2B5CQ41687440-213F706F-8B81-41A8-A4E8-2E7A455B9226Q45099898-0E75AF89-3167-469B-A91B-827A598FB788Q53688076-F54ACBDF-8319-4266-9C61-F705ACE03206
P2860
Biofilm compared to conventional antimicrobial susceptibility of Stenotrophomonas maltophilia Isolates from cystic fibrosis patients.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Biofilm compared to convention ...... from cystic fibrosis patients.
@en
type
label
Biofilm compared to convention ...... from cystic fibrosis patients.
@en
prefLabel
Biofilm compared to convention ...... from cystic fibrosis patients.
@en
P2093
P2860
P356
P1476
Biofilm compared to convention ...... from cystic fibrosis patients.
@en
P2093
Larissa Matukas
Valerie Waters
Yvonne C W Yau
P2860
P304
P356
10.1128/AAC.02215-12
P407
P577
2013-01-07T00:00:00Z